The Ohio State University Comprehensive Cancer Center (OSUCCC) is currently in its 35th year as an NCI designated CCC and is now requesting continued federal support for the next five years. Dr. Caligiuri currently continues in his seventh year as the OSUCCC Director and has since been named CEO of OSU's freestanding James Cancer Hospital. The overall goal remains to reduce cancer morbidity and mortality through continued basic, translational and clinical research. The 239 OSUCCC full, associate or introductory members are currently served by 18 shared resources and are distributed among the our six Research Programs which remain unchanged: Cancer Control, Experimental Therapeutics, Innate Immunity, Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention, and Viral Oncology. Since the last competitive renewal, the OSUCCC has shown significant growth as demonstrated by: 1) the recruitment of 159 faculty focused in basic, translational and clinical cancer research and medicine;2) more than a 80% increase in patient accrual to investigator-initiated trials;3) the addition of 5 new shared resources at an institutional investment of over $4.2 million;4) a 96% increase in total NCI funding despite a period of relatively flat federal funding;5) an 85% increase in publications, 51% of which were collaborative (i.e., inter-, intra-programmatic, or both);5) discovery, preclinical development and administration of two new anti-cancer agents into man, along with additional important advances in basic and clinical cancer research. The OSUCCC has also seen tremendous growth in institutional commitment since 2004 as demonstrated by 1) a ten-fold increase in annual financial support (now approximately $50 million) for the OSUCCC under the control of the Director;2) an additional $7.0 million of cash annually from OSU for research and infrastructure expansion;3) a formal direct reporting relationship to the Executive Vice President and Provost with complete oversight of the University-wide cancer funding initiatives, opportunities and cancer grant submissions;4) A seat on the University President's cabinet providing representation of the CCC at the highest level of the University;5) a six-fold increase in space currently under the sole control of the Director, including new additional dry and wet laboratory and office space for recruitment of additional faculty;6) a written commitment and approval by the OSU Board of Trustees for the expansion of the Cancer Program facilities that will more than double the current square footage under control of the OSUCCC Director in the next five years at a cost of approximately $800 million. With these new resource commitments in place, the OSUCCC is poised for continued significant growth and expansion in the next 5 years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016058-38S1
Application #
8788973
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-12
Project End
2015-11-30
Budget Start
2014-03-13
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$75,000
Indirect Cost
$26,206
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Brasky, Theodore M; Hinton, Alice; Doogan, Nathan J et al. (2018) Characteristics of the Tobacco User Adult Cohort in Urban and Rural Ohio. Tob Regul Sci 4:614-630
Saini, Uksha; Suarez, Adrian A; Naidu, Shan et al. (2018) STAT3/PIAS3 Levels Serve as ""Early Signature"" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube. Cancer Res 78:1739-1750
Olaverria Salavaggione, Gonzalo N; Duggan, Megan C; Carson, William E (2018) Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. Melanoma Res 28:390-397
Jones, Caitlin E; Hammer, Anisha M; Cho, YouJin et al. (2018) Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland. Neoplasia 21:132-145
Fenn, J Daniel; Monsma, Paula C; Brown, Anthony (2018) Axonal neurofilaments exhibit frequent and complex folding behaviors. Cytoskeleton (Hoboken) 75:258-280
Zhang, Lingling; Yu, Jianhua; Wei, Wei (2018) Advance in Targeted Immunotherapy for Graft-Versus-Host Disease. Front Immunol 9:1087
Jasinski, Daniel L; Li, Hui; Guo, Peixuan (2018) The Effect of Size and Shape of RNA Nanoparticles on Biodistribution. Mol Ther 26:784-792
Gordillo, Gayle M (2018) Reply: Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation. Plast Reconstr Surg 141:320e
Ott, Christopher J; Federation, Alexander J; Schwartz, Logan S et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell 34:982-995.e7
Willis, William L; Wang, Linan; Wada, Takuma Tsuzuki et al. (2018) The proinflammatory protein HMGB1 is a substrate of transglutaminase-2 and forms high-molecular weight complexes with autoantigens. J Biol Chem 293:8394-8409

Showing the most recent 10 out of 2602 publications